key: cord-1000809-k0sbj3bb
authors: Yadav, Manisha; Dhagat, Swasti; Eswari, J. Satya
title: Emerging strategies on in silico drug development against COVID-19: challenges and opportunities
date: 2020-08-20
journal: Eur J Pharm Sci
DOI: 10.1016/j.ejps.2020.105522
sha: 8ce91a7f6f43b0afaf334c9bfb556d38f50cf433
doc_id: 1000809
cord_uid: k0sbj3bb

The importance of coronaviruses as human pathogen has been highlighted by the recent outbreak of SARS-CoV-2 leading to the search of suitable drugs to overcome respiratory infections caused by the virus. Due to the lack of specific drugs against coronavirus, the existing antiviral and antimalarial drugs are currently being administered to the patients infected with SARS-CoV-2. The scientists are also considering repurposing of some of the existing drugs as a suitable option in search of effective drugs against coronavirus till the establishment of a potent drug and/or vaccine. Computer-aided drug discovery provides a promising attempt to enable scientists to develop new and target specific drugs to combat any disease. The discovery of novel targets for COVID-19 using computer-aided drug discovery tools requires the knowledge of structure of the coronavirus and the various target proteins present in the virus. Targeting the viral proteins will make the drug specific against the virus, thereby, increasing the chances of viral mortality. Hence, this review provides the structure of SARS-CoV-2 virus along with the important viral components involved in causing infection. It also focuses on the role of various target proteins in disease, the mechanism by which currently administered drugs act against the virus and the repurposing of few drugs. The gap arising from the absence of specific drugs is addressed by proposing potential antiviral drug targets which might provide insights into structure-based drug development against SARS-CoV-2.

The pandemic of COVID-19 has led the world for the emergency search of potential drugs to combat such deadly viral diseases. As per the reports, drugs developed through repurposing of the existing drugs are focused in an order to defeat the pathogenicity of virus. Various target proteins of virus have been identified with the specific mechanism of action. This review article will be focusing on the roles of target protein in disease and how the available antiviral drugs act upon such targets to combat the virus. Apart from that, new insights into the various strategies used for drug and vaccine development would be discussed.

Importance of computer-aided drug discovery has emerged as the potential tool to be used worldwide to work in the direction of structural biology utilizing structure of target proteins.

In an attempt of drug repurposing, computational methods are participating in understanding the mechanism of virus at the molecular level and giving a focused direction to the research with cost-effectiveness and economic viability to benefit the society. Hence, in this review, the approach of using computational tools to discover suitable drugs for COVID-19 is also discussed.

The sudden emergence of viral pneumonia cases in Wuhan city of China in late December 2019 created havoc throughout the world. It is believed to have originated from Huanan Seafood Wholesale Market in Wuhan, China in December 2019 and since then it has spread worldwide. The causal microorganism, later identified as a novel coronavirus, was named as 2019-nCoV or SARS-CoV-2 by World Health Organization (WHO) and the novel coronavirus disease was termed as COVID-19 (Perrella et al. 2020 ). SARS-CoV-2 is a zoonotic virus and it shares similarity with SARS-CoV which was responsible for severe acute respiratory syndrome (SARS) pandemic in early 2000s. The COVID-19 has infected millions of people across the globe causing highly fatality especially among kids and elderly people. As per the reports of WHO, a worldwide total of 19,936,210 COVID-19 cases were reported till August 11, 2020 with 732,499 deaths. America reported the highest number of total positive cases (10,697,832) highest deaths (390,850) till that time followed by Europe with 3,606,373 total cases and 217,278 deaths. The mortality rate of this disease worldwide is approximately 3.7% till date which shows its high transmission rate (World Health Organization 2020).

The origin of the virus is animals from where it jumped to humans. It is thought the virus was transmitted to humans by bats but the host of the virus is still unclear. Other than bats, pangolins are also believed as hosts transmitting coronavirus to humans as the whole genome of pangolin-CoV shares 91.02% identity to SARS-CoV-2 genome . It is also suspected that the bats infected other animal, termed as intermediate hosts which transmitted virus to humans. This can be assumed based on similar cases of coronaviruses, SARS and MERS, wherein the viruses were transmitted from bats to an intermediate hosts before infecting humans , Zheng 2020 .

The first cases of COVID-19 disease indicated animal-to-human transmission of virus as the main mechanism of transmission of this disease. When the number of cases rose without getting exposed to any seafood market or direct contact with animal this theory was eliminated and it was concluded that the transmission of virus is human-to-human. It cannot be neglected that the virus is transmitted before any symptoms develop in the infected person as it has been reported that the asymptomatic individuals are also capable of transmitting the virus (Cascella et al. 2020 ). Hence, isolation or quarantine of the patient is the only way to reduce transmission of the disease.

The SARS-CoV-2 is transmitted through respiratory secretions in the form of droplets and by close contact with the infected person. It is also reported that the faeces of the infected patient also contains coronavirus. Hence, the virus can also be replicated in the digestive tract of the patients and exist there. This suggests the possibility of faecal-oral transmission of the virus (Holshue et al. 2020 . In some cases, the transmission of virus from mother to child post childbirth has also been reported. The new-born of the infected mother was found to be positive for viral nucleic acid but this study lacks scientific evidence (Zhu et al. 2020 ).

The transmission and infection of CoV by consuming virus-infected food has not been reported till date .

The structure of SARS-CoV-2 is similar to other coronaviruses. The coronaviruses consist of positive single-stranded RNA strands with nucleocapsid protein and are enveloped. The viral genome is approximately of 30 kb with a 3'-poly-A tail and a 5'-cap . The SARS-CoV-2 consists of four structural proteins, namely, spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins ( Figure 1) . Spike protein is a transmembrane glycoprotein which protrudes from the surface of virus in a homotrimeric form. This acts as a key therapeutic target. The S-protein is divided into two subunits: S1 and S2. The S1 subunit consists of receptor binding domain (RBD) which binds to ACE2 receptor present in host cell . The S1 subunit shares 40% of amino acid identity with other SARS-CoVs. The S2 subunit consists of a fusion peptide which helps in the fusion of virus with cellular membrane, a transmembrane domain and a cytoplasmic domain. This subunit is highly conserved and hence it could be a potential target for antiviral drugs. The boundary of two subunits consists of a cleavage site which is cleaved by host proteases upstream of the fusion peptide ). This cleavage helps in activation of proteins required to fuse with membrane by permanent conformational changes. The S-protein contains Nlinked glycans which makes it highly glycosylated. The glycans are required for proper folding of S-protein. The fusion and entry of coronavirus into target cells is facilitated by receptor-binding and processing of S-protein by protease. The interaction of S1/S2 with ACE2 (Angiotensin Converting Enzyme 2) of host cells helps in the entry of virus into host cells (Cascella et al. 2020 ).

Among the other proteins, the envelope protein has a role in viral pathogenicity and helps in assembly and release of virus particles. The non-structural proteins (NSPs) help in blocking the innate immune response of the host cells (Lei et al. 2018 , Cascella et al. 2020 ). 

As the structure of SARS-CoV-2 is similar to SARS-CoV, its mechanism of replication and infection in a host cell is also postulated to be same. After entering into human body, the coronavirus binds to enterocytes and pneumocytes where it replicates and forms new virus particles. The virus also targets tubular epithelial cells of kidney, cerebral neuronal cells and immune cells. The spike protein of the virus helps in its attachment with the host-cell protein of target cells. Similar to SARS-CoV, SARS-CoV-2 interacts with angiotensin converting enzyme-2 (ACE-2) in the host cell (Li et al. 2003 . Once into the cell, the virus releases its genome along with nucleocapsid inside the host cells. The two polyproteins, pp1a and pp1b, are produced by ORF1a and ORF1b genes which enable the translation process of the virus using the host cells' ribosomes (Stobart et al. 2013) . Both the polyproteins help in the formation of replication-transcription complex (Te Velthuis et al. 2012 ). The polyproteins are processed by virally encoded protease, namely, chymotrypsinlike protease (3CLpro) or main protease (Mpro) and two-papain-like protease, and produces 16 non-structural proteins or NSPs. All these NSPs have specific function in replication and transcription of viral genome. For example, NSP1 and NSP2 suppress the expression of host gene whereas NSP3 forms a multidomain complex. NSP4 and NSP6 are transmembrane protein and NSP5 is a protease which has a role in replication (Stobart et al. 2013) . NS7 and NSP8 act as primase enzyme (Te Velthuis et al. 2012) . NSP9 is a RNA binding protein which helps in the dimerization of RNA. The dimeric form is important for viral infection.

Disruption of dimerization inhibits the infection by the virus (Egloff et al. 2004 , Hu et al. 2017 ). NSP10 is a cofactor for activation of replicative enzyme (Bouvet et al. 2014 ). NSP12 to NSP16 are enzymes involved in various processes of viral replication and transmission.

NSP12 is RNA dependent RNA polymerase (RdRp) plays an important role in viral replication and transcription and also is a primary drug for some antiviral drugs (Gao et al. 2020 ). NSP13 has helicase activity, NSP14 has exoribonuclease activity and NSP15 has endonuclease activity. NSP16 has methyltransferase activity (J Alsaadi and Jones 2019).

After synthesis of proteins, M (Membrane), E (Envelope) and S (Spike) proteins enter into the endoplasmic reticulum-Golgi intermediate complex (ERGIC) where they make viral envelope or outer cover. The replicated genome binds N (Nucleocapsid) protein and forms ribonucleoprotein (RNP) complex (Narayanan et al. 2000) . The viral particles are released from ERGIC by budding. The mature virions form vesicles which fuse with plasma membrane of host cells and release virus particles into the extracellular space (Nieto-Torres et al. 2011 , de Wit et al. 2016 . Upon infection, SARS-CoV produces excessive immune response in the host cells, also called as "cytokine storm". This releases interleukin 6 which is produced by activated leukocytes and targets various cells and tissues. Interleukin 6 is a proinflammatory cytokine and can cause cytokine release syndrome (CRS). It is an acute systemic inflammatory syndrome which results in fever and multiple organ failure. These also damage lung tissue and, deteriorate function of lung which might result in lung failure in some cases (Ding et al. 2004 , Du et al. 2009 , Cascella et al. 2020 , Prajapat et al. 2020 ).

Due to the lack of specific drugs against SARS-CoV-2, commonly called as COVID-19, the currently available antiviral drugs are being administered to coronavirus-infected patients.

These drugs target different pathways required for viral growth and infection by inhibiting certain proteins or important process of the pathways. Table 1 summarizes the site of inhibition of currently tested drugs for COVID-19.

Two of the common drugs administered worldwide belong to the family of antimalarial drugs, chloroquine and hydroxychloroquine. An aminoquinolone derivative, chloroquine (C 18 H 26 ClN 3 ), was initially developed for the treatment of malaria and extraintestinal amebiasis. Later, it was repurposed to treat HIV, rheumatoid arthritis and systemic lupus erythematosus (Plantone and Koudriavtseva 2018) . It was also used to treat Zika virus . Currently, this drug is undergoing clinical trials against COVID-19 (Colson et al. 2020 ). In the host cell, the drug diffuses through the cell membrane by passive diffusion and enters endosomes, lysosomes and Golgi vesicles. The chloroquine gets trapped into these organelles, gets converted into protonated form and raises the pH of the medium. As release of virus requires low pH and the pH of endosomes is raised, the virus particles cannot fuse and enter into cells. Chloroquine inhibits ACE2 glycosylation at its terminals. As ACE2 is the receptor by which SARS-CoV and SARS-CoV-2 enters cells, the unglycosylated form of ACE2 is unable to interact with SARS-CoV-2 spike protein and hence the entry of virus into the cells is prevented. (Ducharme and Farinotti 1996 , Vincent et al. 2005 , Zhu et al. 2020 Chloroquine inhibits the actions of tumor necrosis factor (TSF), toll-like receptor 9 and glutathione S-transferase whereas it modulates the activity of Angiotensin-converting enzyme (ACE) 2.

Hydroxychloroquine (C 18 H 26 ClN 3 O) is also an aminoquinoline and consists of R and S enantiomers. Similar to the action of chloroquine, hydroxychloroquine also inhibits the formation and entry of virus particles by elevating the pH of endosomes. This drug is also been used for its efficacy against SARS-CoV-2 (Vincent et al. 2005 , Zhu et al. 2020 It is being investigated for the treatment of infections caused by SARS-CoV-2 along with other HIV therapies (Lu 2020 . Umifenovir is an indole-based hydrophobic drug which directly acts as antiviral/host-targeting agents. The drug has direct virucidal activity and host-targeting activity by affecting the stages of viral life cycle. The dual activity of umifenovir might be the reason for its broad-spectrum antiviral activity (Blaising et al. 2014 ). Due to the hydrophobicity of umifenovir, it forms aromatic stacking interactions with tyrosine and tryptophan acting against viruses. The interaction of drug with the plasma membrane might interfere with intracellular trafficking and clathrin-mediated exocytosis (Blaising et al. 2013) or with the lipid envelope of viruses. This may prevent entry of virus in cells (Teissier et al. 2011 , Blaising et al. 2014 ). Its interaction with the viral lipids and proteins also interferes with the viral life cycle.

It is a synthetic prodrug which is metabolized into guanosine nucleoside and interferes with the synthesis of viral mRNA. It is used for treating viral hemorrhagic fevers including Venezuelan hemorrhagic fever, Crimean-Congo hemorrhagic fever, Lasser fever, and

Hantavirus infection and hepatitis C. The ribavirin prodrug is activated to ribavirin mon-, di-, and triphosphate metabolites by adenosine kinase. Ribavirin triphosphate binds to the active site of viral mRNA polymerase and inhibits its activity. Due to this, the replication of virus is reduced or defective virions are produced. Ribavirin also inhibits inosine monophosphate dehydrogenase in host cells resulting in decreased pool of GTP. This leads to reduced viral protein synthesis and limited replication of viral genomes (Te et al. 2007 ). Another mechanism of antiviral activity of ribavirin is that it causes mutation in virus that result in early termination of RNA in hepatitis C virus. Ribavirin also stimulates the humoral immune response in host cells and down-regulates the genes involved in apoptosis and interferon inhibition (Martin and Jensen 2008) . Ribavirin inhibits the catalytic subunit of RNA-directed RNA polymerase in influenza virus and targets RNA-directed RNA polymerase L in HPIV-2 and genome polyprotein in DENV-2.

Information about the structure and metabolic pathways of coronavirus and pathophysiology protein is the envelope-associated protein and is another important protein that is expressed by some of the CoV strains only (Li 2016) . CoV RNA genome is packed inside the nucleocapsid and is further covered by envelope protein (Guo et al. 2008) .

Originally some coronaviruses are found to cause enzootic diseases which are naturally limited to their animal hosts but it has crossed the species barrier of animal-human and proceeded towards the zoonotic infections in human (Rest and Mindell 2003 , Lau et al. 2005 , Hon et al. 2008 , Chan et al. 2013 , Lu et al. 2015 . The jumps of cross-species barriers accordingly allowed coronaviruses such as SARS-CoV (South Asian respiratory syndrome) and MERS-CoV (Middle Eastern respiratory syndrome) to form virulent human viruses.

Evidently, the resoluteness of such infections and lack of approved and efficient prognosis highlight the urgency for detailed and thorough investigation of molecular biology of coronavirus majorly focusing on structural and accessory proteins (Masters 2006 , Kilianski et al. 2013 , Kilianski and Baker 2014 , Lou et al. 2014 . Fusion inhibitors, live and attenuated vaccines have proven as a promising approach in treatment but these also require in-depth information of molecular biology of CoV (Masters 2006 , DeDiego et al. 2007 , Netland et al. 2010 , Graham et al. 2012 , Heald-Sargent and Gallagher 2012 .

The encoding of majorly four structural proteins through coronaviral genome, namely, spike protein (S), nucleocapsid, membrane protein (M) and envelop protein (E), are required for producing a complete structure of viral particle (Mortola and Roy 2004 , Masters 2006 , Wang et al. 2017 . The probable target proteins of SARS-CoV-2 (Bhatia et al. 2020 ) as reported in protein data bank has been enlisted with PDB IDs in Table 2 . Due to the similarity of SARS-

CoV-2 genome with other coronaviruses, the knowledge of target proteins in them can also be used to develop drugs against SARS-CoV-2. Therefore, the target proteins of coronaviruses, along with their PDB IDs, are mentioned in Table 3 . Crystal structure of spike protein receptor-binding domain from a predicted SARS coronavirus human strain complexed with human receptor ACE2

Spike protein is a type-I tetrameric (TM) protein with a clove shape ( The spike protein contains three segments which are ectodomain region (ED), trimeric region (TM) and an intracellular short tail domain (S1) (Pradesh et al. 2014 ). The S1 receptorbinding domain (3 S1 heads) and membrane fusion S2 subunit (TM stalk) together on Cterminal comprise the ectodomain. S1 domain acts as major antigen on the virus surface and

consists of a receptor binding domain (RBD) (Ortego et al. 2007) . S1 domain has two main components that are N and C terminal domains (NTD and CTD) (Ortego et al. 2007 , Ou et al. 2020 ). RBD (consists 14 residues) of spike protein (SARS-CoV) interacts with the 18 residues of ACE2 (Fehr et al. 2015) . Amino acid residue R453 of RBD and K341 of ACE-2 play an important role for this contact. Point mutation of R441 or D454 has potential to disturb the binding capability with ACE-2. The S2 subunit consists of two heptad repeat regions known as HR 1 and HR 2 and a hydrophobic fusion peptide. The virus is called as CoV due to the gathering of spike proteins on the outer surface of virion in the trimeric form which gives it the resemblance of a crown. The spike protein supports the entry of virus into the host and is responsible for activating immune response of host cell against CoV (Gerna et al. 2007 ). The primary interaction of S1 domain and host receptor (for SARS-CoV: ACE2

receptor and for MERS-CoV: PP4) and further S2 segment mediates the fusion of viral membrane and host and subsequently allows the entry of RNA genome of coronavirus inside the host cells. Hence, these proteins are proposed as targets of importance for drug discovery (Gerna et al. 2007 , Ortego et al. 2007 , Woo et al. 2009 , Fehr et al. 2015 .

The envelop protein is the most versatile and the smallest (8.4-12 kDa size) of structurally major TM proteins of CoV family. E protein is expressed in abundance during the replication cycle in the infected cell and very small portion of this protein gets incorporated into virion envelope (Narayanan et al. 2000 , Escors et al. 2001 , Venkatagopalan et al. 2015 . It is comprised of two distinct domains which are a charged cytoplasmic tail and a hydrophobic domain (Narayanan et al. 2000) . It is majorly localised at the intracellular trafficking site such as Golgi, ER and ERGIC (Corse and Machamer 2000) . Here, it takes part in assembly and budding of CoV (Nieto-Torres et al. 2011). Recombinant CoVs with the lack of E protein are found with reduced viral titres, incompetent progeny, significantly reduced yield propagation and crippled viral maturation which demonstrates the importance of envelope protein for production and maturation of virus (Curtis et al. 2002 , Ortego et al. 2002 , Kuo and Masters 2003 , DeDiego et al. 2007 , Ortego et al. 2007 ). Hence, E protein has a significant role in morphogenesis of virus. According to studies, envelop protein has role in coordinating with other proteins and modulating protein activities (Narayanan et al. 2000) . It acts as a virulent factor as well (Gil et al. 2020 ). E protein form the ion channel through oligomerisation and can be targeted by hexamethylene amiloride to block the associated E protein ion channel activities in mammalian cells which expressed SARS-CoV E protein (Bos et al. 1996, Corse and Machamer 2003) .

The membrane protein, a structural protein of high abundance, has role in defining the shape of viral envelop (Neuman et al. 2011) . It performs the job of shape maintenance through interacting with other major structural CoV proteins (Masters 2006) , incorporating Golgi complex into new virions and stabilizing N proteins (Nucleocapsid) (Corse et al. 2000) . M protein is referred as a central organiser for the assembly of coronavirus. Three TM domains characterizes the M protein with C terminal (long) inside and N-terminal (short) located at outside (Vennema et al. 1996 , Baudoux et al. 1998 

The structure of N-protein is conserved amongst various members of the CoV family. N is the protein which primarily takes part in binding with CoV-RNA genome to make the nucleocapsid unlike other structurally major proteins ( (Vabret et al. 2008 , Bande et al. 2015 . As Central linker (CL) is serine and arginine rich region, hence it contains a high number of phosphorylation sites (Lou et al. 2014) . Intrinsically disordered regions (IDRs) of C terminal play an important role in the oligomerization of nucleocapsid protein and interactions of N-M proteins (Curtis et al. 2002) .

Remarkably, localization of N protein into ER-Golgi complex region proposes its function in assembling and budding as well (Tooze et al. 1984 , Klumperman et al. 1994 . Transient expression of nucleocapsid shows increased production of VLPs in some coronaviruses, stating its requirement for the formation of envelope (Boscarino et al. 2008 , Siu et al. 2008 , Ruch and Machamer 2011 , Ruch and Machamer 2012 . RNP complex formation and maintenance are the major functions of N protein Intrinsically disordered regions (IDRs) of C terminal plays an important role in the oligomerization of nucleocapsid protein and interactions of N-M proteins (Curtis et al. 2002) . Apart from regulating transcription and replication of viral RNA, it inhibits the translation of protein via EF1 alpha-mediated action, alteration in host cell-cycle, host cell metabolism and apoptosis (Nucleocapsids are reported for CDK4 inhibition) in the host cell (Vabret et al. 2008 , Lee 2015 . N protein takes part in inhibition of cytokinesis mediated cell proliferation in human peripheral blood (Ortego et al. 2002) .

3C-like protease protein, also known as 3CLpro is found in homodimeric form. The active site of 3CLpro consists of a cystine-histidine (Cys-His) dyad which is responsible for its protease activity (Kilianski et al. 2014) . Mutation on Ser139 and Phe140 eradicates the 

Papain-like proteases (PLpro) is responsible for N-terminal cleavage of PP and generates three non-structural proteins (NSP 1, 2 and 3) (Surya et al. 2013 , Lee 2015 . PLpro consists of a 316 amino acid long catalytic core domain responsible for cleaving substrates of replicase. In conjunction, LXGG sequence supports cleavage (Verdiá-Báguena et al. 2013) . It is found that zinc and its conjugates, in higher doses, are capable for inhibiting SARS proteases of both the types CLpro and PLpro (Hung and Sheng 2002) .

The hemagglutinin esterase enzyme is localized into the coronavirus envelope, specifically amid beta-coronaviridae. The HE enzyme is a marker of evolution of influenza and coronavirus. HE acts as a mediator for reversible attachment with O-acetylated-sialic-acids through the functioning as lectins and receptor-disrupting enzyme. Crystal structure of interaction of HE complexed with sialic acid is available to visualize in protein data bank with PDB ID: 3CL5 (Gerek et al. 2009 ).

Helicase/NTpase has a prominent role in the viral central dogma (Gerek et al. 2009 ). It is a member of SF1. The preferred substrates of HE are ATP, dCTP and dATP. Apart from that all NTPs are also hydrolysed by this (Jimenez-Guardeno et al. 2015) . Toxicity and nonspecificity are the major issues in developing helicase inhibitors as non-specificity leads to severe toxicity . Although, instead of having theoretical limitations, HE is getting recognized increasingly as a druggable target for the various conditions of disease (Hogue and Machamer 2008) .

Nsp15 is recently mapped and a conserved protein among the families of coronavirus. It is one of the essential proteins for the viral lifecycle and virulence. As per earlier studies, it was supposed to be responsible for viral replication directly but recent studies proposed Nsp15 to help in viral replication through interfering the immune response of host ).

The non-structural protein15 from SARS-CoV-2 has 89 percent similarity with the protein of previous outbreak of SARS-CoV. The published studies of 2010 on SARS-CoV-1 reveal that the viral replication can be slowed down by inhibiting Nsp15. The studies available suggest the drug development targeting Nsp15 could be potential against COVID-19. Nsp15 is reported with PDB ID: 6VWW and revealed to scientific community at protein data bank (RCSB) on 3 rd March, 2020.

Drug repurposing also known as drug repositioning and reprofiling is an efficient strategy of drug discovery from existing drugs. The approach significantly reduces the time and cost as compared to discovery of novel drug / de novo drug designing and random clinical trials , Cheng et al. 2017 , Cheng et al. 2019 . Computer-aided drug discovery facilitates novel hypotheses to test efficient drug repurposing , Cheng et al. 2018 . Conventional structure-based approaches have limitations where three-dimensional structures of target protein are not available. This is a major issue while targeting human and viral proteins. Because of the rapid evolution of viral genome, targeting single viral protein is not feasible . Even though cellular factor of host is required for replication of human coronavirus during infection, efficient identification of systematic protein-protein interaction of host and virus offers a systematic way for elucidation of viral infection mechanism. Consequently, targeting viral proteins and antiviral targets of cell, that is, host-virus interactome can be a potentially novel strategy for exploring the treatment of viral infection (Dyall et al. 2014) . Drug repurposing promises to identify a viable strategy, in a time-critical manner, for the screening of antiviral agents against SARS-CoV-2. It offers a combinational approach acting with 'double-hit effect' to combat coronavirus infection with more successful chances and clinical translation (Senanayake 2020) . The earlier screening of broad-spectrum antiviral agents (BSAA) have been introduced and tested safe in clinical trials and now been explored as promising repurposing candidates . Drug repurposing has been resulted in reaching for phase III clinical trials for drugs, such as, remdesivir, lopinavir, favipiravir and hydroxyquinone, etc. Conceptually, promiscuity of replication mechanism of virus and host-target interaction is taken as advantage to explore BSAAs (Bösl et al. 2019) .

Another limiting dimension of phenotypic screening is the hit compounds with low potency as single agent, hence their dose with maximum tolerability is found subtherapeutic (Sun et al. 2016) . To resolve such issues, two or more drugs are evaluated which are acting on various signalling pathways involved in viral replication with least redundancy. Highthroughput screening to sought out synergistic combination from compound libraries could be an another strategy targeting host-virus interaction for emerging infectious diseases, which narrow down the research spectrum of individual agents (Bösl et al. 2019 , Cheng et al. 2019 .

Such strategies are promising to address weakly-active BSAAs by potentially reducing dosage, improving efficiency, reducing time and drug development cost, lowering toxicity and minimizing occurrence of secondary resistance (Zheng et al. 2018) . Notably, the lack of specificity of broad-spectrum antiviral agents leads to implications with highly virulent strains and emergence of drug resistance. An example of a non-structural coronavirus protein NSP14-exon with cofactor NSP10 acts on nucleotide-mismatch repair caused by the exposure of ribavirin (nucleoside analog) and hence has potential to negate antiviral efficiency of BSAA (Ferron et al. 2018) . Simultaneously, the notion of determining drug repositioning strategy has competition with structure-based drug designing of small molecule therapeutics and preventative vaccines and off-targeted specificity. The interaction of coronavirus spike glycoprotein and human enzyme ACE2 as a port for cellular invasion has driven a way for rapid development of antibodies and vaccines (Salvatori et al. 2020) . Such strategies possibly hindered through the genetic drift of viruses due to the potential of blunt antigenicity of epitope (Letko et al. 2020 , Wrapp et al. 2020 .

Another important factor in the quest of drug repurposing comprises issues with patent protection under international and national policies. COVID-19 global health emergency with the magnitude of such level seeks courageous international response from the political and government level. Also, rapid actions of regulatory authority are required for minimized financial hurdles and updated guidelines on drug licensing via reprofiling wherever necessary. Simultaneously, such efforts are vital acts, behind the scene, while seeking indications on existing compounds.

The spike protein of coronavirus binds to the cell membrane of host via a receptor-mediated interaction which facilitates its entry in the host cell. The computational studies have indicated similarity in mechanism of SARS-CoV-2 with SARS virus. It has highest affinity with receptor ACE2 (Xu et al. 2020) . Spike protein of SARS-CoV-2 has structural similarity with SARS virus spike protein where 73% region is conserved and variability is majorly in the region of protein for host cell interaction.

The other computation docking model is focusing on 3C like protease (3CLpro) which controls the various major viral functions. It consists of highly conserved SARS-CoV catalytic domain (Anand et al. 2003) . Replication process is one of a major function of 3CLpro due to which it is prospected as ideal target for drug designing (Bacha et al. 2004) . It is reported in protein data bank with PDB ID: 6LU7 . Remdesivir, zanamvir, saquinavir and indinavir are the potential hits inhibiting 3CLpro protease. Some off-label medications are also indicated through studies such as adeflavin, FAD (flavin adenine dinucleotide), coenzyme A. These can also be beneficial for the treatment of COVID-19.

Spike and protease, both the proteins are essential for the viral transmission and to cause virulence. Inhibition of both or any of these proteins can reduce the severity of infection. The efforts have been focusing on the competitive inhibition of binding to their natural substrates (Hall Jr and Ji 2020) . As per the docking studies, RNA polymerase inhibitors and HIV protease inhibitors are also found to be promising to bind with SARS-CoV-2 target proteins.

Subsequently, a protein synthesis inhibitor methisazone, CGP42112A as antigiotensin receptor agonist (ACE inhibitor) and compound ABT450 as nsp3-4A inhibitor have come up as suitable treatment options (Shah et al. 2020) . According to another in silico study conducted, some of the commercial drugs such as valrubicin, colistin, icatibant, epirubicin, bepotastine, epoprostenol, aprepitant, vapreotide, perphanazine and caspofungin are also found to bind with same binding site of lopinavir/ritonavir (Cai et al. 2020) .

Compound library of known bioactive agents from databases like ZINC15 (includes 3447 entries of FDA & Drug Bank approved compounds) facilitates to explore the potential inhibitors against the catalytic domains of these targets (Sterling and Irwin 2015, Hall Jr et al. 2020 ). Utilization of approved compounds from database leads to quicker trials and reduced efforts in getting approval from food and drug regulatory agencies. The drug reprofiling with the aid of computational drug discovery approaches helps in exploring therapeutics which can be promising for the treatment of coronavirus disease (Hall Jr et al. 2020) .

In a study, an integrated drug reprofiling methods with a network platform based upon pharmacology, drug targets in the human protein-protein (P-P) interaction network and quantification of interplay within human coronavirus and host interactome (HCoV-Host) have been implemented using network strategies (Gordon et al. 2020 ). It was observed through studies on 15 whole genome sequences of HCoV using phylogenetic analysis that the similarity between SARS-CoV-2 and SARS-CoV is 79.7%. The studies specified that the nucleocapsid and envelope proteins of novel coronavirus (SARS-CoV-2) are two evolutionary conserved regions with sequence similarities of 89.6% and 96% respectively with SARS-CoV. A network proximity studies on hCoV-host interactions and drug targets using potential antiviral repurposable drugs were validated using enrichment analyses of human coronavirus induced transcriptomics data and drug-gene signature in human cell lines.

The studies summarised rapid identification of potential drug combinations and candidate repositionable drugs against SARS-CoV-2 ).

Studies of multiple sequence alignment of COVID-19 protease with orf1ab polyprotein and PDB template identification as 4MM3_B have revealed various residues which are highly conserved. This includes the ligand binding sites of COVID-19 protease (Thr 75, Arg 141, Gln175 and His 176).

Viral enzyme 3-chymotrypsin-like cysteine protease is an essential for life cycle of coronavirus which controls the process of replication is a proven target for SARS-CoV and MERS-CoV. Computational studies revealed the similarity of genomic sequence of SARS-nCoV-2 with SARS-CoV (ul Qamar et al. 2020) . Notably the re-emerging and new disease outbreaks like current pandemic of COVID-19 can potentially shake the global health system.

It is evident from the output of multiple sequence alignment that the ligand binding sites (Thr 75, Arg141, Gln 175 and His 176) were found to be conserved amongst the sequences of COVID-19 proteases. The current computational studies provide structural and molecular insight about COVID-19 proteases which might in deciphering drug-target interaction with some known potential protease inhibitors (Eleftheriou et al. 2020, Mothay and Ramesh 2020) .

Multiple sequence alignment is a potential computational techniques for the identification of conserved domains of COVID-19 proteases. It was carried out using orf1ab polyprotein from pneumonia virus of Wuhan seafood market (YP_009724389.1). The best template was identified with PDB using Clustal Omega from SWISS MODEL server (Sievers et al. 2011 

Receptor binding domain is majorly targeted for drug design studies for spike proteins. A study reported with a similar peptide sequence of RBD is capable of hampering ACE2

interaction of S1-RBD domain which has role in preventing viral entry in the host cell (studies conducted on Vero cells, IC 50 -40 μM) (Hu et al. 2005 , Han et al. 2006 , Du et al. 2009 ). Another peptide sequence (OC43-HR2P) derived from HR2 (heptad repeat) region of S2 domain (HCoV-OC43) optimized as EK1 has exhibited fusion inhibitory role among pan-CoV (Xia et al. 2019) . Spike protein specific monoclonal antibodies CR301 and 80R can block the interaction of spike protein with ACE2, hence neutralize the SARS-CoV infection (Du et al. 2009 ). M396 monoclonal antibody is found with competitive role for receptor binding domain (RBD) (Prabakaran et al. 2006) . Herbal products such as polyphenolic compounds like gallocatechin gallate and catechin are found to show inhibitory activity targeting NTD against HCoV (Roh 2012) . Similarly, Cterminal domain (CTD) of Nucleocapsid (N) protein helps in oligomerization on C-terminal.

As per the studies, competition with the process of oligomerization via a C-terminal sequence of tail peptide (N377-389) has significant inhibitory role on virus (titer concentration of 300 μM) (Lo et al. 2013 ).

The SARS coronavirus genome encodes numerous proteins. A major component of coronavirus genome is replicase gene, encodes 16 non-structural proteins (NSPs) in two large forms of PPs (PP1a and PP1ab). Cysteine proteases of two types act on PPs and release

NSPs. The cleavage of C terminal of PPs is done by chymotrypsine-like cysteine protease (3Cpro or M pro -main protease). The M pro , also known as papain-like protease (PL pro ), processes the N-terminal region (Lindner et al. 2005) . PL pro cuts the first three cleavage site of PPs and CLpro cleaves the rest eleven sites. This ultimately release 16 NSPs (Jo et al. 2020 ). Some peptidomimetic compounds and metal conjugates showed inhibitory action against 3CLpro. Various small molecules also act as an inhibitor such as arylboronic acid, thiophenecarboxylate, derivatives of quinolinecarboxylate and analogs of phthalhyrazidesubstituted ketoglutamate (Hsu et al. 2005) . Inhibition of M pro is reported with some flavonoids (Jo et al. 2020) . Crystal structure of M pro with N3 inhibitor complex is reported with PDB ID: 2AMQ . HIV protease inhibitors ritonavir and lopinavir also has inhibitory activity on M pro .

Lopinavir/ritonavir drug combination therapy to target viral protease and a membrane fusion inhibitor umifenovir which targets viral entry, together is approved the treatment of HIV and influenza. Currently, different combination of these drugs are considered for phase IV clinical trials for COVID-19 associated with pneumonia (ClinicalTrials.gov ID: NCT04255017) (Chang et al. 2016 . Remdesivir, an RNA-dependent RNA polymerase inhibitor was under investigation level of phase III for moderate and mild SARS-CoV-2 infection (ClinicalTrials.gov Identifier: NCT04252664) . This study has been suspended in China on April 2020 due to the lack of eligible patients. Preclinical studies on remdesivir have shown activity against SARS-CoV and MERS-CoV (Gordon et al. 2020 ). It has shown remarkable studies in a controlled and randomised trial on Ebola virus infection and demonstrated antiviral effects (Mulangu et al. 2019) . Alongside other agents evaluated at Phase III level for combination therapy include hydroxychloroquine (antimalarial) according to promising data of in vitro studies which has been completed in April 2020 (ClinicalTrials.gov Identifier: NCT04261517) . Apart from immunomodulating properties of choloroquine, it exhibits antiviral action at entry and afterentry stages of coronavirus infection. It has shown potential synergistic role with BSAAs and found to enhance antiviral effect of remdesivir (Wrapp et al. 2020) . At the initial stages, favipiravir, an RNA polymerase inhibitor in combination therapy, is also on phase II of clinical trial for pneumonia associated with novel coronavirus disease (Chinese Clinical Trial Registry Identifier: ChiCTR2000029544) (Registry 2020) . Apart from that, preclinical studies on ribonucleic analog ribavirin have also shown activity against SARS-CoV-2 under in vitro investigations (Wrapp et al. 2020) .

Solving and mapping three-dimensional structure of coronavirus helps scientists to conclude how a viral replication process in human cells can be interfered. It is now clear that complete assembly of structural proteins of coronavirus is not required to form an infectious and complete virion. This suggests the dispensability of some structural proteins or possibly, coronavirus might encode some proteins which overlap compensatory functions additionally.

However, each protein plays a primary role as a structural component of virus particle, but these have also found to participate in some of the aspects of its replication cycle. Some viral proteins have been participating in a flexible multienzyme complex system which facilitates compensatory low fidelity of viral replication. There are viable strategies to enable proofreading of coronavirus RNA and maintain genetic integrity and, consequently, rendering some degree of evolution or freedom to mutate.

Here, definitely high-throughput screening and virtual screening come to rescue (Fischer et al. 2020) . Hence, it is a need to screen drugs with their affinity to perturb the functionality of such systems in CoV. This includes the possibility of targeting catalytic subunits such as nsp14-Exon and critical sites with allosteric effects where conformational changes are caused by conserved residues in the entire RNA repair complex of virus. Henceforth, the search should be focusing on identification of inhibitors for viral nuclease.

Computer-aided drug discovery techniques indicated high affinity of antiviral drugs such as ritonavir, oseltamivir, remdesivir and favipiravir with COVID-19 main protease in complex with N3 while antimalarial drugs (hydroxyquinone and chloroquine) show high affinity interaction with spike glycoprotein-human ACE2 complex, which suggest that abovementioned molecules can be used as suitable against target proteins of SARS-CoV-2.

We can antedate the notion of drug reprofiling for emerging coronavirus disease through scrutinization based on these studies. Conclusively, this is not only a fight against COVID-19 but also for the various emerging viral diseases and evolutionarily arising microbial and viral infections. The sole concept of new antiviral and medicinal products, that is, one drug for one virus vs. one drug for multiple virus and multiple drugs for one virus are the challenges for their clinical indications.

Coronavirus susceptibility to the antiviral remdesivir

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

The proximal origin of SARS-CoV-2

Discovery and development of safe-in-man broad-spectrum antiviral agents

Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro

Progress and challenges toward the development of vaccines against avian infectious bronchitis

Coronavirus pseudoparticles formed with recombinant M and E proteins induce alpha interferon synthesis by leukocytes

A Summary of Viral Targets and Recently Released PDB IDs of SARS-CoV-2

Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking

Arbidol as a broad-spectrum antiviral: an update

The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus

Envelope protein palmitoylations are crucial for murine coronavirus assembly

Common Nodes of Virus-Host Interaction Revealed Through an Integrated Network Analysis

Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes

Experimental treatment with favipiravir for COVID-19: an open-label control study

Features, evaluation and treatment coronavirus (COVID-19)

Interspecies transmission and emergence of novel viruses: lessons from bats and birds

Structure-based virtual screening and experimental validation of the discovery of inhibitors targeted towards the human coronavirus nucleocapsid protein

Network-based approach to prediction and population-based validation of in silico drug repurposing

Drug repurposing: new treatments for zika virus infection?

Systems biologybased investigation of cellular antiviral drug targets identified by gene-trap insertional mutagenesis

Improving therapy of severe infections through drug repurposing of synergistic combinations

Chloroquine for the 2019 novel coronavirus

Infectious bronchitis virus E protein is targeted to the Golgi complex and directs release of virus-like particles

The cytoplasmic tails of infectious bronchitis virus E and M proteins mediate their interaction

Heterologous gene expression from transmissible gastroenteritis virus replicon particles

Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV

Origin and evolution of RNA-dependent RNA polymerase

Molecular interactions in the assembly of coronaviruses

Assembly of the coronavirus envelope: homotypic interactions between the M proteins

protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

SARS and MERS: recent insights into emerging coronaviruses

A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo

Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways

The spike protein of SARS-CoV-a target for vaccine and therapeutic development

Clinical pharmacokinetics and metabolism of chloroquine

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection

The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world

Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus

Replicating Vaccines: Birkhauser Advances in Infectious Diseases

The membrane M protein carboxy terminus binds to transmissible gastroenteritis coronavirus core and contributes to core stability

An E460D substitution in the NS5 protein of tick-borne encephalitis virus confers resistance to the inhibitor Galidesivir (BCX4430) and also attenuates the virus for mice

Coronaviruses: an overview of their replication and pathogenesis

Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA

The Antiviral Drug Arbidol Inhibits Zika Virus

Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Identification of specificity and promiscuity of PDZ domain interactions through their dynamic behavior

Human respiratory coronavirus HKU1 versus other coronavirus infections in Italian hospitalised patients

COVID-19: Drug targets and potential treatments

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease

Pathogenetic mechanisms of severe acute respiratory syndrome

A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor

Coronavirus puts drug repurposing on the fast track

Drug researchers pursue new lines of attack against COVID-19

Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses

Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence

The broad-spectrum antiviral drug arbidol inhibits foot-and-mouth disease virus genome replication

From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design

Coronavirus structural proteins and virus assembly

First case of 2019 novel coronavirus in the United States

Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus

Mechanism of the maturation process of SARS-CoV 3CL protease

Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library

Structural basis for dimerization and RNA binding of avian infectious bronchitis virus nsp9

Ritonavir-boosted protease inhibitors in HIV therapy

Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses

PDZ domains: structural modules for protein complex assembly

Membrane binding proteins of coronaviruses

Inhibition of SARS-CoV 3CL protease by flavonoids

Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors

Assessing activity and inhibition of MERS-CoV papain-like and 3C-like proteases using luciferase-based biosensors

The architecture of SARS-CoV-2 transcriptome

Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2

Pre-fusion structure of a human coronavirus spike protein

Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding

The small envelope protein E is not essential for murine coronavirus replication

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

Porcine epidemic diarrhea virus: an emerging and re-emerging epizootic swine virus

Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice

Structure, function, and evolution of coronavirus spike proteins

Antiviral activity of arbidol hydrochloride against herpes simplex virus I in vitro and in vivo

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

The missing link in coronavirus assembly retention of the avian coronavirus infectious bronchitis virus envelope protein in the pre-Golgi compartments and physical interaction between the envelope and membrane proteins

Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target

The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme

Accessory proteins of SARS-CoV and other coronaviruses

The crytal structure of 2019-nCoV main protease in complex with an inhibitor N3

Oligomerization of the carboxyl terminal domain of the human coronavirus 229E nucleocapsid protein

Current progress in antiviral strategies

Bat-to-human: spike features determining 'host jump'of coronaviruses SARS-CoV, MERS-CoV, and beyond

2020. Drug treatment options for the 2019-new coronavirus (2019-nCoV) Biosci Trends

Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials

Ribavirin in the treatment of chronic hepatitis C

The molecular biology of coronaviruses

The coronavirus nucleocapsid is a multifunctional protein

Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system

Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock

A randomized, controlled trial of Ebola virus disease therapeutics

Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells

The molecular docking study of potential drug candidates showing anti-COVID-19 activity by exploring of therapeutic targets of SARS-CoV-2

Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease

A structural analysis of M protein in coronavirus assembly and morphology

Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein

Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis

Envelope glycoprotein interactions in coronavirus assembly

Absence of E protein arrests transmissible gastroenteritis coronavirus maturation in the secretory pathway

Generation of a replication-competent, propagation-deficient virus vector based on the transmissible gastroenteritis coronavirus genome

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune crossreactivity with SARS-CoV

The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses

Editorial-Novel Coronavirus 2019 (Sars-CoV2): a global emergency that needs new approaches

Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a minireview

Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody

Coronavirus infection in equines: A review

Drug targets for corona virus: A systematic review

Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation

A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy

Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates

SARS associated coronavirus has a recombinant polymerase and coronaviruses have a history of host-shifting

A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide

Use of favipiravir to treat Lassa virus infection in macaques

The hydrophobic domain of infectious bronchitis virus E protein alters the host secretory pathway and is important for release of infectious virus

The coronavirus E protein: assembly and beyond

SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines

Drug repurposing strategies for COVID-19

silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sciences

Cell entry mechanisms of SARS-CoV-2

Structural basis of receptor recognition by SARS-CoV-2

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation

Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega

The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of viruslike particles

Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein

ZINC 15-ligand discovery for everyone

Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity

Drug combination therapy increases successful drug repositioning

HIV-1 assembly, budding, and maturation. Cold Spring Harbor perspectives in medicine 2

Structural and Functional Aspects of Viroporins in Human Respiratory Viruses: Respiratory Syncytial Virus and Coronaviruses By Wahyu Surya, Montserrat Sams and Jaume Torres

Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir

Mechanism of action of ribavirin in the treatment of chronic hepatitis C

The SARS-coronavirus nsp7+ nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension

Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol

Replication of coronavirus MHV-A59 in sac-cells: determination of the first site of budding of progeny virions

Combating HIV resistance-focus on darunavir

Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19

A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia

A Trial of Remdesivir in Adults With Mild and Moderate COVID-19

Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants

Human (non-severe acute respiratory syndrome) coronavirus infections in hospitalised children in France

Coronavirus envelope (E) protein remains at the site of assembly

Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope protein genes

Analysis of SARS-CoV E protein ion channel activity by tuning the protein and lipid charge

Coronavirus E protein forms ion channels with functionally and structurally-involved membrane lipids

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

An analysis based on decade-long structural studies of SARS 3, JVI Accepted Manuscript Posted Online 29

MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques

Structural and functional basis of SARS-CoV-2 entry by using human ACE2

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters

Coronavirus diversity, phylogeny and interspecies jumping

Coronavirus disease (COVID-19) Situation Report-204

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

The SARS-CoV-2 outbreak: what we know

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

Design of wide-spectrum inhibitors targeting coronavirus main proteases

Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors

Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak

Study shows pangolins may have passed new coronavirus from bats to humans

SARS-CoV-2: an emerging coronavirus that causes a global threat

Drug repurposing screens and synergistic drugcombinations for infectious diseases

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia

We are thankful to National Institute of Technology Raipur India for providing the necessary facilities to prepare the manuscript and permission to publish it.

Authors declare no conflict of interest.